Table 3.
Cost-effectiveness results.
| Intervention cost (£m/100k population) | Obesity disease cost (£m/100k population) | Total cost (£m/100k population) | Total QALY per 100k population | Incremental cost (£m/100K population) | Incremental QALY (per 100K population) | ICER (vs. next best alternative) | ICER (vs. baseline) | |
|---|---|---|---|---|---|---|---|---|
| Base case analysis | ||||||||
| Baseline | £0 | £2898 | £2898 | 1,135,676 | – | – | – | – |
| WMP1 | £94 | £2814 | £2909 | 1,154,944 | £11 | 19,269 | £557 | £557 |
| VLCD added to WMP1 | £220 | £2812 | £3032 | 1,155,963 | Dominated | Dominated | Dominated | £6628 |
| WMP2 | £135 | £2798 | £2933 | 1,158,386 | Ext Dom. | Ext Dom. | Ext Dom. | £1540 |
| Look AHEAD | £889 | £2754 | £3643 | 1,167,101 | Ext Dom. | Ext Dom. | Ext Dom. | £23,725 |
| RYGB Surgery | £2024 | £2295 | £4319 | 1,276,038 | £1411 | 121,094 | £11,648 | £10,126 |
| BMI regain sensitivity analysis | ||||||||
| Baseline | £0 | £2898 | £2898 | 1,135,676 | Dominated | Dominated | Dominated | – |
| VLCD added to WMP1 | £220 | £2840 | £3060 | 1,150,251 | Dominated | Dominated | Dominated | £11,152 |
| WMP1 | £94 | £2834 | £2928 | 1,151,112 | Dominated | Dominated | Dominated | £1965 |
| WMP2 | £135 | £2740 | £2875 | 1,168,178 | – | – | – | Dominant |
| Look AHEAD | £889 | £2666 | £3555 | 1,179,771 | Ext Dom. | Ext Dom. | Ext Dom. | £14,906 |
| RYGB Surgery | £2024 | £2295 | £4319 | 1,276,038 | £1444 | 107,860 | £13,392 | £10,126 |
Dominated: An intervention that is both more costly and less effective than a comparator. A dominated intervention doess not offer good value for money and is therefore excluded from the calculation of ICERs.
Ext Dom: Extendedly dominated: An intervention that is excluded because an alternative intervention can deliver greater QALY gains for a lower ICER.
BMI Body mass index, ICER Incremental cost-effectiveness ratio, N/A Not applicable, QALY Quality adjusted life year, RYGB Roux-en-Y gastric bypass surgery, WMP1 Weight Management Programme 1, WMP2 Weight Management Programme 2, VLCD Very Low Calorie Diet.